Palisade Bio, University of California Team Up For Target Identification, Discovery, Development

by Vandana Singh, Benzinga Editor
July 13, 2021 10:18 AM | 26 seconds read |
  • Palisade Bio Inc PALI has entered into an exclusive license with the Regents of the University of California, expanding its technology for detecting enzymatic protease activity in human clinical samples. 
  • Under the terms of this agreement, the Company receives a worldwide exclusive license to patent rights covering certain engineered substrates and their use in measuring degradative enzymes for disease conditions.
  • Price Action: PALI shares are up 3.28% at $3.78 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsPenny StocksHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!